Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Heron Therapeutics Inc (HRTX) Price & Performance

First Citizens BancShares IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Heron Therapeutics Inc — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $25.04B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: First Citizens BancShares Inc is far larger — about 407.4× Heron Therapeutics Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

FCNCAHRTX
Market Cap
$25.04B$61.47M
Sector
Sector/ThematicHealth
52-Week High
$2.25K$1.49
52-Week Low
$1.64K$0.32
Dividend Yield
0.37%
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.

FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX